Loading
Led FAST-Forward, which cut breast radiotherapy from three weeks to one with no loss of effectiveness.
Murray Brunt (Keele University) was chief investigator of FAST-Forward, the UK trial of 4,000 women showing that 26 Gy in five fractions over one week is non-inferior to 40 Gy in 15 fractions for local recurrence and normal tissue effects after breast conservation, a result adopted rapidly during the COVID-19 pandemic and now standard in many countries. He also led the FAST trial of five-fraction schedules over five weeks.
Shares IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer and the tags radiotherapy, breast.
Shares IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer and the tags radiotherapy, breast.
Shares IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer and the tags radiotherapy, breast.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares HR-positive / HER2-negative breast cancer and the tag radiotherapy.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
Shares HR-positive / HER2-negative breast cancer and the tag breast.
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.